Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary ...

The Advanced Research Projects Agency for Health (ARPA-H) has awarded a new tranche of funds for companies and institutions ...

Opus Genetics, Inc. (Nasdaq: IRD) (the "Company”, "Opus Genetics” or "Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene ...

ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...

A new study reveals that axon formation is driven by an internal molecular zipper protein complex called Arp2/3.

The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ ...

Scientists engineered human cells to perform binary calculations using genetic circuits, advancing cell therapies and ...

Does informing people about their genetic risk of obesity help them change their habits and lose excess weight? A study, published in the journal Obesity Reviews by scientists including researchers ...

Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology plat ...

The federal agency ARPA-H earmarked $43 million for Philadelphia researchers to advance gene therapies for rare diseases.

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, ...